Spyre Therapeutics Prices $350 Million Public Offering at $85 Per Share
Spyre Therapeutics (SYRE) announced that it priced a public offering of 4.12 million shares of common stock at $85 per share, generating expected gross proceeds of approximately $350 million. The underwritten offering is part of the company’s strategy to raise capital for its operations and development programs. The offering includes an option for the underwriters to purchase up to 617,249 additional shares at the same price, which could increase total gross proceeds by approximately $52.5 million if exercised in full. Spyre Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with rare and severe diseases.
Tickers: $SYRE